(EMAILWIRE.COM, January 21, 2020 ) Increasing patient preference for nasal drug delivery as a result of easy administration & better efficacy and growing adoption of self-administration practices are some of the major factors driving the growth of the nasal drug delivery technology market. Intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.

The global nasal drug delivery technology market is projected to reach USD 64.20 billion by 2021 from USD 44.00 billion in 2016, at a CAGR of 6.5% during the forecast period.

Increasing patient preference for nasal drug delivery as a result of easy administration and better efficacy

Intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers. This can majorly be attributed to the non-invasive nature of this route of delivery and the fact that drug absorbability is higher through the nasal route. In addition, the nasal route offers a less hostile environment as compared to the gastro-intestinal route; this enables better absorption of drugs. Moreover, nasal drug delivery, unlike some other routes of drug delivery, dose not require any sterile method for administering drugs into the body.The easy administration of these drugs plays a crucial role in improving the compliance to drug therapies among patients, which in turn drives patient outcomes.Considering these factors, the preference for nasal drug delivery is increasing among patients as well as healthcare providers.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=192818058

Homecare settings drive the growth of nasal drug delivery market

Homecare settings

Homecare settings is the largest and the fastest growing end-user segment in the nasal drug delivery technology market. The growth of this segment is attributed to increasing patient preference for self-administration of drugs among patients and the increasing usage of nasal powders and sprays that can be easily administered by patientsMoreover, the self-administration of drugs in the home care settings helps patients save time and money, thereby bringing down healthcare costs incurred by the patient.
Drug administration in the home care settings is most beneficial for long term therapy.

Hospitals

Hospitals are among the major end users for nasal drug delivery; the substantial growth in the number of patients suffering from chronic rhinitis is a key market driver for this end-user segment.

Several nasal drugs require trained staff for their administration so as to avoid over-dosage; this is expected to further drive growth for this end-user segment.

The overuse of nasal sprays results in various complications, such as irritation in the nasal mucosa, dryness within the nose, temporary burning sensation, and runny nose. This is because nasal sprays comprise a chemical that is used for shrinking blood vessels in the nose. Thus, the continuous use of these sprays may render the blood vessels to be less responsive to the medication.Also, overuse of nasal sprays usually causes addiction among patients, which may lead to serious long-term conditions such as chronic sinusitis. According to the U.S. Department of Health & Human Services, in 2014, there were 29.4 million adults diagnosed with sinusitis in the U.S.; this represented 12.3% of thetotal population in the country. In the nasal route of drug delivery, doctors and physicians usually cannot control the dosage of medicine consumed by patients. This can result in decongested nose and other chronic problems. These drawbacks are expected to limit the growth of the nasal drug delivery technology market (specifically for nasal sprays).

Major Leading Companies

Prominent players in the nasal drug delivery technology market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca plc. (U.S.), AptarGroup (U.S.), and GlaxoSmithKline plc (U.K.).

Inquiry about Nasal Drug Delivery Technology Market @
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=192818058

Contact Information:
MarketsandMarkets™
Mr. Shelly Singh
Tel: 1-888-600-6441
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results